Skip to main content

Table 4 Multiple-adjusted HRs for OS by baseline BMI level, stratified by covariates

From: Overweight/obese status associates with favorable outcome in patients with metastatic nasopharyngeal carcinoma: a 10-year retrospective study

Stratification covariate

No. of patients

Underweight (HRa)

Normal weight [HR (95% CI)a]

Overweight/obese [HR (95% CI)a]

P b

Age (years)

0.675

 <45

419

1.0

1.01 (0.74–1.38)

0.74 (0.50–1.09)

 

 ≥45

400

1.0

0.76 (0.55–1.06)

0.54 (0.37–0.79)

 

Sex

0.680

 Men

681

1.0

0.82 (0.64–1.04)

0.59 (0.44–0.79)

 

 Women

138

1.0

1.29 (0.67–2.45)

0.93 (0.45–1.94)

 

UICC T category

0.471

 T1–2

369

1.0

0.84 (0.60–1.17)

0.78 (0.52–1.17)

 

 T3–4

450

1.0

0.88 (0.65–1.19)

0.49 (0.34–0.70)

 

UICC N category

0.501

 N0–1

417

1.0

0.83 (0.61–1.14)

0.55 (0.37–0.82)

 

 N2–3

402

1.0

0.86 (0.60–1.18)

0.67 (0.46–0.98)

 

Metastasis onset

0.551

 Synchronous

272

1.0

0.94 (0.60–1.49)

0.55 (0.33–0.90)

 

 Metachronous

547

1.0

0.80 (0.62–1.04)

0.67 (0.48–0.92)

 

Lung metastasis

0.761

 Absent

469

1.0

0.92 (0.69–1.24)

0.66 (0.46–0.95)

 

 Present

350

1.0

0.78 (0.54–1.12)

0.62 (0.40–0.94)

 

Liver metastasis

0.098

 Absent

574

1.0

0.70 (0.54–0.91)

0.45 (0.32–0.62)

 

 Present

245

1.0

1.39 (0.22–2.19)

1.46 (0.88–2.43)

 

Bone metastasis

0.051

 Absent

382

1.0

0.83 (0.58–1.18)

0.76 (0.50–1.14)

 

 Present

437

1.0

0.91 (0.68–1.23)

0.57 (0.39–0.82)

 

Solitary lesion

0.062

 No

701

1.0

0.90 (0.72–1.14)

0.60 (0.45–0.80)

 

 Yes

118

1.0

0.35 (0.14–0.86)

0.44 (0.17–1.13)

 

Number of involved sites

0.331

 One

545

1.0

0.72 (0.57–0.99)

0.53 (0.38–0.74)

 

 Two or more

274

1.0

1.11 (0.75–1.66)

0.84 (0.52–1.33)

 

Treatment modality

0.055

 CT

607

1.0

0.92 (0.71–1.19)

0.56 (0.41–0.77)

 

 CT + LT

212

1.0

0.74 (0.46–1.21)

0.89 (0.52–1.52)

 
  1. OS overall survival; BMI body mass index; UICC Union of International Cancer Control; CT chemotherapy; LT local therapy; HR hazard ratio; CI confidence interval
  2. aAdjusted for age, sex, UICC T category, UICC N category, onset of metastasis, solitary lesion, lung metastasis, liver metastasis, bone metastasis, number of involved sites, and treatment modality, excluding stratification covariate
  3. b P for interaction